Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Caribou Biosciences (CRBU) Shares Outstanding (Diluted Average) (2021 - 2025)

Caribou Biosciences (CRBU) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $93.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) rose 3.4% to $93.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $93.4 million through Dec 2025, up 3.4% year-over-year, with the annual reading at $93.4 million for FY2025, 3.4% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $93.4 million at Caribou Biosciences, roughly flat from $93.0 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $93.4 million in Q4 2025, with the low at $10.3 million in Q2 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $69.9 million, with a median of $68.9 million recorded in 2023.
  • The sharpest move saw Shares Outstanding (Diluted Average) surged 492.08% in 2022, then grew 0.9% in 2023.
  • Over 5 years, Shares Outstanding (Diluted Average) stood at $31.7 million in 2021, then skyrocketed by 92.02% to $60.8 million in 2022, then rose by 21.39% to $73.8 million in 2023, then rose by 22.37% to $90.3 million in 2024, then rose by 3.4% to $93.4 million in 2025.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $93.4 million, $93.0 million, and $93.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.